Correspondence 0001493152-23-027180 from CDT Equity Inc. (CDT)
CDT Equity Inc.
Date: Aug. 8, 2023 · CIK: 0001896212 · Accession: 0001493152-23-027180
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271903
Letter
Division of Corporation Finance Office of Manufacturing Murphy Canyon Acquisition Corp. Amendment No. 2 to Registration Statement on Form S-4 Filed July 28, 2023 File No. 333-271903
Dear Mr. Howes and Ms. Crotty,
On behalf of Murphy Canyon Acquisition Corp. (the “Company”), this letter responds to comment provided by the staff of the Division of Corporation Finance (the “Staff”), of the U.S. Securities and Exchange Commission (the “Commission”) to the undersigned on August 7, 2023, regarding the Company’s Amendment No. 2 to Registration Statement on Form S-4 (the “Registration Statement”) filed with the Commission on July 28, 2023. Changes made in response to the Staff’s comment have been made in our amendment to the Registration Statement (the “Amended Registration Statement”), which is being filed with the Commission contemporaneously with the submission of this letter.
For convenience, the Staff’s comments have been restated below and the Company’s responses are set out immediately under the restated comments. Unless otherwise indicated, defined terms used herein have the meanings set forth in the Registration Statement.
Amendment No. 2 to Form S-4 filed July 28, 2023
Business of Conduit Pharmaceuticals Limited
Our Initial Pipeline: AZD1656 and AZD5904, page 150
1. We note your response to our prior comment 8 and the table now included on page 150, notably the last column of the table. Please revise your disclosure to explain how the listed candidates may reach commercialization “following completion of Phase II” rather than following the successful completion of Phase III clinical trials.
Response: The Company has revised the disclosure on page 150 of the Amended Registration Statement in response to the Staff’s comment.
Should you have any questions regarding the foregoing, please do not hesitate to contact our counsel Avital Perlman of Sichenzia Ross Ference LLP at (212) 930-9700.
Sincerely,
Jack
K. Heilbron
Show Raw Text
CORRESP
1
filename1.htm
Murphy
Canyon Acquisition Corp.
4995
Murphy Canyon Road, Suite 300
San
Diego, CA 92123
August
8, 2023
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Manufacturing
100
F Street, NE
Washington,
D.C. 20549
Attn:
Tyler Howes and Laura Crotty
Re:
Murphy
Canyon Acquisition Corp.
Amendment
No. 2 to Registration Statement on Form S-4
Filed
July 28, 2023
File
No. 333-271903
Dear
Mr. Howes and Ms. Crotty,
On
behalf of Murphy Canyon Acquisition Corp. (the “Company”), this letter responds to comment provided by the staff of
the Division of Corporation Finance (the “Staff”), of the U.S. Securities and Exchange Commission (the “Commission”)
to the undersigned on August 7, 2023, regarding the Company’s Amendment No. 2 to Registration Statement on Form S-4 (the “Registration
Statement”) filed with the Commission on July 28, 2023. Changes made in response to the Staff’s comment have been made
in our amendment to the Registration Statement (the “Amended Registration Statement”), which is being filed with the
Commission contemporaneously with the submission of this letter.
For
convenience, the Staff’s comments have been restated below and the Company’s responses are set out immediately under the
restated comments. Unless otherwise indicated, defined terms used herein have the meanings set forth in the Registration Statement.
Amendment
No. 2 to Form S-4 filed July 28, 2023
Business
of Conduit Pharmaceuticals Limited
Our
Initial Pipeline: AZD1656 and AZD5904, page 150
1.
We note your response to our prior comment 8 and the table now included on page 150, notably the last column of the table. Please
revise your disclosure to explain how the listed candidates may reach commercialization “following completion of Phase
II” rather than following the successful completion of Phase III clinical trials.
Response: The Company has revised the disclosure
on page 150 of the Amended Registration Statement in response to the Staff’s comment.
Should
you have any questions regarding the foregoing, please do not hesitate to contact our counsel Avital Perlman of Sichenzia Ross Ference
LLP at (212) 930-9700.
Sincerely,
Jack
K. Heilbron
Chief
Executive Officer
cc:
Avital
Perlman, Esq.